Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy: Part 3, Imatinib for Chronic Myeloid Leukemia (CML)

摘要

This assessment of imatinib for treatment of CML was performed at the request of the Centers for Medicare and Medicaid Services (CMS) and is designed to inform the likely health outcomes associated with a current demonstration project which provides for payment for certain oral medications, including imatinib for CML, that are prescribed as replacements for other drugs currently covered under Medicare Part B.